Home > Boards > US Listed > Biotechs > Argenx SE (ARGX)

https://thefly.com/landingPageNews.php?id=2794139 Argenx data concerns over rescue therapy unfounded

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
riche Member Profile
 
Followed By 1
Posts 29
Boards Moderated 0
Alias Born 12/15/10
160x600 placeholder
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/14/2020 1:44:41 PM
argenx announces closing of global offering GlobeNewswire Inc. - 11/12/2019 4:00:00 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 11/8/2019 5:19:46 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 11/8/2019 5:15:58 PM
argenx announces full exercise of underwriters’ option to purchase additional ADSs GlobeNewswire Inc. - 11/8/2019 1:00:00 AM
argenx raises $484 million in gross proceeds in a global offering GlobeNewswire Inc. - 11/6/2019 10:45:00 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 11/6/2019 5:28:06 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 11/6/2019 9:25:37 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 10/24/2019 7:18:59 AM
argenx reports third quarter 2019 financial results and provides business update GlobeNewswire Inc. - 10/24/2019 1:00:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 10/15/2019 4:37:15 PM
argenx to Present at Morgan Stanley 17th Annual Global Healthcare Conference GlobeNewswire Inc. - 9/3/2019 1:00:00 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 8/12/2019 2:14:21 PM
argenx to Present at 2019 Wedbush PacGrow Healthcare Conference GlobeNewswire Inc. - 8/6/2019 1:00:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 8/1/2019 6:19:00 AM
argenx reports half year 2019 financial results and second quarter business update GlobeNewswire Inc. - 8/1/2019 1:00:00 AM
argenx to report half year 2019 financial results and second quarter business update on August 1, 2019 GlobeNewswire Inc. - 7/25/2019 1:00:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 5/28/2019 6:10:44 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 5/22/2019 6:11:23 AM
argenx announces pipeline expansion and “argenx 2021” vision to build integrated immunology company at 2019 R&D Day GlobeNewswire Inc. - 5/22/2019 1:00:00 AM
Confidential Treatment Order (ct Order) Edgar (US Regulatory) - 5/9/2019 5:11:37 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 5/9/2019 6:52:46 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 5/8/2019 4:07:37 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 4/10/2019 10:36:38 AM
Annual and Transition Report (foreign Private Issuer) (20-f) Edgar (US Regulatory) - 3/26/2019 4:42:53 PM
riche   Tuesday, 10/02/18 04:01:07 AM
Re: riche post# 4
Post # of 10 
https://thefly.com/landingPageNews.php?id=2794139 Argenx data concerns over rescue therapy unfounded, says Piper Jaffray Argenx last week reported positive Phase II immune thrombocytopenia data on efgartigimod showing clean safety and clear efficacy, Piper Jaffray analyst Edward Tenthoff tells investors in a research note. He points out that twelve, or 46%, efgartigimod-treated patients achieved clinically meaningful platelet improvement. The analyst views concern over rescue therapy and bleeding events as unfounded and reiterates an Overweight rating on Argenx shares with a $154 price target. Bioscience liked last!Lampi, Bioscience waardeerde(-n)



Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist